[go: up one dir, main page]

DE69723721D1 - Gelformulierungen zur topischen arzneimittelzufuhr - Google Patents

Gelformulierungen zur topischen arzneimittelzufuhr

Info

Publication number
DE69723721D1
DE69723721D1 DE69723721T DE69723721T DE69723721D1 DE 69723721 D1 DE69723721 D1 DE 69723721D1 DE 69723721 T DE69723721 T DE 69723721T DE 69723721 T DE69723721 T DE 69723721T DE 69723721 D1 DE69723721 D1 DE 69723721D1
Authority
DE
Germany
Prior art keywords
gel formulations
drug
topical
drug delivery
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69723721T
Other languages
English (en)
Other versions
DE69723721T2 (de
Inventor
M Beaurline
J Roddy
A Tomai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3M Co
Original Assignee
Minnesota Mining and Manufacturing Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minnesota Mining and Manufacturing Co filed Critical Minnesota Mining and Manufacturing Co
Application granted granted Critical
Publication of DE69723721D1 publication Critical patent/DE69723721D1/de
Publication of DE69723721T2 publication Critical patent/DE69723721T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69723721T 1996-12-03 1997-12-01 Gelformulierungen zur topischen arzneimittelzufuhr Expired - Lifetime DE69723721T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/759,992 US5939090A (en) 1996-12-03 1996-12-03 Gel formulations for topical drug delivery
US759992 1996-12-03
PCT/US1997/021995 WO1998024436A2 (en) 1996-12-03 1997-12-01 Gel formulations for topical drug delivery

Publications (2)

Publication Number Publication Date
DE69723721D1 true DE69723721D1 (de) 2003-08-28
DE69723721T2 DE69723721T2 (de) 2004-04-15

Family

ID=25057713

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69723721T Expired - Lifetime DE69723721T2 (de) 1996-12-03 1997-12-01 Gelformulierungen zur topischen arzneimittelzufuhr

Country Status (18)

Country Link
US (2) US5939090A (de)
EP (1) EP0942724B1 (de)
JP (1) JP4615633B2 (de)
KR (1) KR100503716B1 (de)
AT (1) ATE245422T1 (de)
AU (1) AU723897B2 (de)
BR (1) BR9713677B1 (de)
CA (1) CA2273094C (de)
CZ (1) CZ301713B6 (de)
DE (1) DE69723721T2 (de)
DK (1) DK0942724T3 (de)
ES (1) ES2200206T3 (de)
HU (1) HU229599B1 (de)
IL (1) IL130065A (de)
NO (1) NO325684B1 (de)
NZ (1) NZ335821A (de)
PT (1) PT942724E (de)
WO (1) WO1998024436A2 (de)

Families Citing this family (163)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5741908A (en) 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
UA67760C2 (uk) 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
US6518280B2 (en) 1998-12-11 2003-02-11 3M Innovative Properties Company Imidazonaphthyridines
US20020058674A1 (en) 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
CA2361936C (en) * 1999-01-08 2009-06-16 3M Innovative Properties Company Formulations comprising imiquimod or other immune response modifiers for treating mucosal conditions
EP1495758A3 (de) * 1999-01-08 2005-04-13 3M Innovative Properties Company Zubereitungen, enthaltend Imiquimod oder andere Immunantwort modifizierende Verbindungen, zur Behandlung von mukosalen Erkrankungen
US6486168B1 (en) 1999-01-08 2002-11-26 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US6558951B1 (en) * 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
US6756382B2 (en) * 1999-06-10 2004-06-29 3M Innovative Properties Company Amide substituted imidazoquinolines
US6331539B1 (en) * 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6541485B1 (en) 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
US6573273B1 (en) * 1999-06-10 2003-06-03 3M Innovative Properties Company Urea substituted imidazoquinolines
US6916925B1 (en) 1999-11-05 2005-07-12 3M Innovative Properties Co. Dye labeled imidazoquinoline compounds
US6376669B1 (en) 1999-11-05 2002-04-23 3M Innovative Properties Company Dye labeled imidazoquinoline compounds
JP3436512B2 (ja) * 1999-12-28 2003-08-11 株式会社デンソー アクセル装置
US6787342B2 (en) * 2000-02-16 2004-09-07 Merial Limited Paste formulations
US6894060B2 (en) * 2000-03-30 2005-05-17 3M Innovative Properties Company Method for the treatment of dermal lesions caused by envenomation
JP2004508851A (ja) * 2000-06-22 2004-03-25 スリーエム　イノベイティブ　プロパティズ　カンパニー 粘膜表面を治療するためのシステムおよび方法
DE10033853A1 (de) * 2000-07-12 2002-01-31 Hexal Ag Transdermales therapeutisches System mit hochdispersem Siliziumdioxid
AU2001281304B2 (en) 2000-08-15 2006-05-25 Surmodics, Inc. Medicament incorporation matrix
US20020055517A1 (en) * 2000-09-15 2002-05-09 3M Innovative Properties Company Methods for delaying recurrence of herpes virus symptoms
JP2002145777A (ja) * 2000-11-06 2002-05-22 Sumitomo Pharmaceut Co Ltd アラキドン酸誘発皮膚疾患治療剤
US6660735B2 (en) * 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
JP2005500510A (ja) * 2000-12-08 2005-01-06 スリーエム イノベイティブ プロパティズ カンパニー インターフェロンαを選択的に誘導する化合物を同定するための選別法
US6664264B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6667312B2 (en) 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6660747B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6545017B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
JP2008531580A (ja) * 2000-12-08 2008-08-14 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答修飾因子の標的化送達のための組成物および方法
US6677348B2 (en) * 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
US6545016B1 (en) * 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US6664265B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
UA75622C2 (en) * 2000-12-08 2006-05-15 3M Innovative Properties Co Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon
US6525064B1 (en) 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
US6664260B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
US6677347B2 (en) * 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US7226928B2 (en) * 2001-06-15 2007-06-05 3M Innovative Properties Company Methods for the treatment of periodontal disease
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
WO2003020889A2 (en) * 2001-08-30 2003-03-13 3M Innovative Properties Company Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules
EP1455700A4 (de) * 2001-11-16 2007-02-14 3M Innovative Properties Co Verfahren und zusammensetzungen im zusammenhang mit irm-verbindungen und toll-rezeptor-pfaden
JP4447914B2 (ja) * 2001-11-29 2010-04-07 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答調節物質を含む医薬品
CA2365732A1 (en) * 2001-12-20 2003-06-20 Ibm Canada Limited-Ibm Canada Limitee Testing measurements
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US7030129B2 (en) * 2002-02-22 2006-04-18 3M Innovative Properties Company Method of reducing and treating UVB-induced immunosuppression
CN1674894A (zh) * 2002-06-07 2005-09-28 3M创新有限公司 醚取代的咪唑并吡啶
EP1380596B1 (de) * 2002-07-08 2007-12-05 Eastman Kodak Company Organische ladungstransportpolymere enthaltend ladungstransporteinheiten und silangruppen und daraus hergestellte silsesquioxan zusammensetzungen
CN1671412B (zh) 2002-08-15 2010-05-26 3M创新有限公司 免疫刺激组合物及刺激免疫反应的方法
US6818650B2 (en) * 2002-09-26 2004-11-16 3M Innovative Properties Company 1H-imidazo dimers
AU2003287324A1 (en) * 2002-12-11 2004-06-30 3M Innovative Properties Company Gene expression systems and recombinant cell lines
AU2003287316A1 (en) * 2002-12-11 2004-06-30 3M Innovative Properties Company Assays relating to toll-like receptor activity
JP2006513212A (ja) 2002-12-20 2006-04-20 スリーエム イノベイティブ プロパティズ カンパニー アリール／ヘタリール置換されたイミダゾキノリン
EP2572715A1 (de) 2002-12-30 2013-03-27 3M Innovative Properties Company Immunstimulatorische Kombinationen
JP2006517974A (ja) * 2003-02-13 2006-08-03 スリーエム イノベイティブ プロパティズ カンパニー Ｉｒｍ化合物およびトル様受容体８に関する方法および組成物
WO2004075865A2 (en) * 2003-02-27 2004-09-10 3M Innovative Properties Company Selective modulation of tlr-mediated biological activity
EP1601365A4 (de) 2003-03-04 2009-11-11 3M Innovative Properties Co Prophylaktische behandlung von uv-induzierter epidermaler neoplasie
KR20050107497A (ko) * 2003-03-07 2005-11-11 쓰리엠 이노베이티브 프로퍼티즈 컴파니 1-아미노 1ｈ-이미다조퀴놀린
US7163947B2 (en) * 2003-03-07 2007-01-16 3M Innovative Properties Company 1-Amino 1H-imidazoquinolines
WO2004080293A2 (en) * 2003-03-13 2004-09-23 3M Innovative Properties Company Methods for diagnosing skin lesions
KR20050109562A (ko) * 2003-03-13 2005-11-21 쓰리엠 이노베이티브 프로퍼티즈 컴파니 피부의 질을 개선시키는 방법
US7179253B2 (en) * 2003-03-13 2007-02-20 3M Innovative Properties Company Method of tattoo removal
US20040192585A1 (en) 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
US20040265351A1 (en) * 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
CA2521682A1 (en) * 2003-04-10 2004-12-16 3M Innovative Properties Company Delivery of immune response modifier compounds using metal-containing particulate support materials
EP1617845A4 (de) * 2003-04-28 2006-09-20 3M Innovative Properties Co Zusammensetzungen und verfahren zur induktion von opioid-rezeptoren
AR044466A1 (es) * 2003-06-06 2005-09-14 3M Innovative Properties Co Proceso para la preparacion de imidazo [4,5-c] piridin-4-aminas
US6943255B2 (en) * 2003-06-06 2005-09-13 3M Innovative Properties Company Process for imidazo[4,5-c]pyridin-4-amines
KR20060054371A (ko) * 2003-07-31 2006-05-22 쓰리엠 이노베이티브 프로퍼티즈 컴파니 캡슐화 및 제어된 방출을 위한 조성물
US8211906B1 (en) 2003-08-05 2012-07-03 Scherrer Lawrence C Method of inhibiting growth of neoplastic cells and inhibiting infection by administering an immune enhancer drug
AU2004264330A1 (en) * 2003-08-05 2005-02-24 3M Innovative Properties Company Infection prophylaxis using immune response modifier compounds
CA2535117A1 (en) 2003-08-12 2005-03-03 3M Innovative Properties Company Oxime substituted imidazo-containing compounds
EP1653959B1 (de) * 2003-08-14 2015-05-27 3M Innovative Properties Company Lipid-modifizierte modifikatoren der immunantwort
JP2007504145A (ja) * 2003-08-25 2007-03-01 スリーエム イノベイティブ プロパティズ カンパニー 免疫刺激性の組み合わせおよび治療
WO2005020912A2 (en) 2003-08-25 2005-03-10 3M Innovative Properties Company Delivery of immune response modifier compounds
MY145983A (en) 2003-08-27 2012-05-31 3M Innovative Properties Co Aryloxy and arylalkyleneoxy substituted imidazoquinolines
JP2007504172A (ja) * 2003-09-02 2007-03-01 スリーエム イノベイティブ プロパティズ カンパニー 粘膜に関連した症状の処置に関する方法
JP2007504269A (ja) 2003-09-05 2007-03-01 スリーエム イノベイティブ プロパティズ カンパニー Ｃｄ５＋ｂ細胞リンパ腫の治療方法
WO2005029037A2 (en) * 2003-09-17 2005-03-31 3M Innovative Properties Company Selective modulation of tlr gene expression
US8871782B2 (en) 2003-10-03 2014-10-28 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
US20090075980A1 (en) * 2003-10-03 2009-03-19 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and Analogs Thereof
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
TW200526656A (en) 2003-10-03 2005-08-16 3M Innovative Properties Co Pyrazolopyridines and analogs thereof
JP2007509987A (ja) * 2003-10-31 2007-04-19 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答調節剤化合物による好中球活性化
AU2004291122A1 (en) 2003-11-14 2005-06-02 3M Innovative Properties Company Hydroxylamine substituted imidazo ring compounds
AU2004291101A1 (en) * 2003-11-14 2005-06-02 3M Innovative Properties Company Oxime substituted imidazo ring compounds
US8778963B2 (en) * 2003-11-25 2014-07-15 3M Innovative Properties Company Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
EP1687307B1 (de) 2003-11-25 2016-01-06 3M Innovative Properties Company Substituierte imidazoringsysteme und verfahren
US6943470B2 (en) * 2003-12-02 2005-09-13 Siemens Westinghouse Power Corporation Air gap baffle assembly for gas-cooled turbine generator and method of installing
US20050226878A1 (en) * 2003-12-02 2005-10-13 3M Innovative Properties Company Therapeutic combinations and methods including IRM compounds
US8940755B2 (en) * 2003-12-02 2015-01-27 3M Innovative Properties Company Therapeutic combinations and methods including IRM compounds
AU2004315771A1 (en) * 2003-12-04 2005-08-25 3M Innovative Properties Company Sulfone substituted imidazo ring ethers
US8802853B2 (en) 2003-12-29 2014-08-12 3M Innovative Properties Company Arylalkenyl and arylalkynyl substituted imidazoquinolines
WO2005066172A1 (en) * 2003-12-29 2005-07-21 3M Innovative Properties Company Piperazine, [1,4]diazepane, [1,4]diazocane, and [1,5]diazocane fused imidazo ring compounds
WO2005067500A2 (en) * 2003-12-30 2005-07-28 3M Innovative Properties Company Enhancement of immune responses
AU2004312508A1 (en) 2003-12-30 2005-07-21 3M Innovative Properties Company Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
CA2559607C (en) * 2004-03-15 2013-02-19 3M Innovative Properties Company Immune response modifier formulations and methods
TW200612932A (en) 2004-03-24 2006-05-01 3M Innovative Properties Co Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
JP2007532572A (ja) * 2004-04-09 2007-11-15 スリーエム イノベイティブ プロパティズ カンパニー 免疫反応調整剤を送達させるための方法、組成物および調製物
BRPI0510430A (pt) * 2004-04-28 2007-10-30 3M Innovative Properties Co composições e métodos para vacinação mucosal
US20050267145A1 (en) * 2004-05-28 2005-12-01 Merrill Bryon A Treatment for lung cancer
US20080015184A1 (en) * 2004-06-14 2008-01-17 3M Innovative Properties Company Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines
US8017779B2 (en) 2004-06-15 2011-09-13 3M Innovative Properties Company Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
US20070259881A1 (en) * 2004-06-18 2007-11-08 Dellaria Joseph F Jr Substituted Imidazo Ring Systems and Methods
WO2006065280A2 (en) 2004-06-18 2006-06-22 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
US8026366B2 (en) 2004-06-18 2011-09-27 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
WO2006038923A2 (en) 2004-06-18 2006-04-13 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
AU2005283085B2 (en) * 2004-06-18 2012-06-21 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US8541438B2 (en) 2004-06-18 2013-09-24 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US20060045886A1 (en) * 2004-08-27 2006-03-02 Kedl Ross M HIV immunostimulatory compositions
PL1789042T3 (pl) * 2004-09-02 2012-09-28 3M Innovative Properties Co Układy pierścieni 1-alkoksy 1H-imidazo i sposoby
WO2006029115A2 (en) 2004-09-02 2006-03-16 3M Innovative Properties Company 2-amino 1h imidazo ring systems and methods
US20090270443A1 (en) * 2004-09-02 2009-10-29 Doris Stoermer 1-amino imidazo-containing compounds and methods
US20080193468A1 (en) * 2004-09-08 2008-08-14 Children's Medical Center Corporation Method for Stimulating the Immune Response of Newborns
WO2006042254A2 (en) * 2004-10-08 2006-04-20 3M Innovative Properties Company Adjuvant for dna vaccines
US20110070575A1 (en) * 2004-12-08 2011-03-24 Coley Pharmaceutical Group, Inc. Immunomodulatory Compositions, Combinations and Methods
US8080560B2 (en) * 2004-12-17 2011-12-20 3M Innovative Properties Company Immune response modifier formulations containing oleic acid and methods
CA2592904C (en) 2004-12-30 2015-04-07 3M Innovative Properties Company Chiral fused [1,2]imidazo[4,5-c] ring compounds
EP1833479A2 (de) * 2004-12-30 2007-09-19 Takeda Pharmaceutical Company Limited 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-aminethanesulfonat und 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-aminmethansulfonat
AU2005326708C1 (en) 2004-12-30 2012-08-30 3M Innovative Properties Company Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
US8436176B2 (en) * 2004-12-30 2013-05-07 Medicis Pharmaceutical Corporation Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine
EP2394650A1 (de) 2004-12-30 2011-12-14 3M Innovative Properties Co. Verwendung von Resiquimod zur Behandlung von Hautmetastasen
EP1844201B1 (de) 2005-02-04 2016-08-24 3M Innovative Properties Company Wässrige gelformulierungen mit immunreaktionsmodifikatoren
CA2597324C (en) 2005-02-09 2015-06-30 Coley Pharmaceutical Group, Inc. Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines
CA2602083A1 (en) 2005-02-09 2006-08-09 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted thiazolo(4,5-c) ring compounds and methods
JP2008532933A (ja) 2005-02-11 2008-08-21 コーリー ファーマシューティカル グループ，インコーポレイテッド 置換イミダゾキノリン類および置換イミダゾナフチリジン類
CA2597587A1 (en) 2005-02-11 2006-08-17 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
WO2006098852A2 (en) 2005-02-23 2006-09-21 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinolines
CA2598437A1 (en) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Method of preferentially inducing the biosynthesis of interferon
EP1851220A2 (de) 2005-02-23 2007-11-07 3M Innovative Properties Company Hydroxyalkylsubstituierte imidazonaphthyridine
CA2598656A1 (en) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinoline compounds and methods
MX2007011112A (es) 2005-03-14 2007-11-07 Graceway Pharmaceuticals Llc Metodo para tratar queratosis actinica.
EP1869043A2 (de) 2005-04-01 2007-12-26 Coley Pharmaceutical Group, Inc. Pyrazolopyridin-1,4-diamine und analoge davon
US7943636B2 (en) 2005-04-01 2011-05-17 3M Innovative Properties Company 1-substituted pyrazolo (3,4-C) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
CA2605808A1 (en) * 2005-04-25 2006-11-02 3M Innovative Properties Company Immunostimulatory compositions
CN101300254A (zh) 2005-09-09 2008-11-05 科利制药集团公司 N－{2－[4－氨基－2－(乙氧基甲基)－1H－咪唑并[4,5－c]喹啉－1－基]－1,1－二甲基乙基}甲磺酰胺的酰胺和氨基甲酸酯衍生物和方法
ZA200803029B (en) * 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
US8889154B2 (en) 2005-09-15 2014-11-18 Medicis Pharmaceutical Corporation Packaging for 1-(2-methylpropyl)-1H-imidazo[4,5-c] quinolin-4-amine-containing formulation
JP5247458B2 (ja) 2005-11-04 2013-07-24 スリーエム・イノベイティブ・プロパティーズ・カンパニー ヒドロキシ及びアルコキシ置換１ｈ−イミダゾキノリン及び方法
JP2009522296A (ja) * 2005-12-28 2009-06-11 スリーエム イノベイティブ プロパティズ カンパニー 皮膚のｔ細胞リンパ腫の治療
EP3085373A1 (de) 2006-02-22 2016-10-26 3M Innovative Properties Company Konjugate zur modifizierung von immunreaktionen
WO2007106854A2 (en) 2006-03-15 2007-09-20 Coley Pharmaceutical Group, Inc. Hydroxy and alkoxy substituted 1h-imidazonaphthyridines and methods
WO2008008432A2 (en) 2006-07-12 2008-01-17 Coley Pharmaceutical Group, Inc. Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods
EP1889609B1 (de) * 2006-07-18 2019-05-22 Meda AB Schaumformulierungen zur Modifikation der Immunantwort
WO2008016475A2 (en) * 2006-07-31 2008-02-07 3M Innovative Properties Company Immune response modifier compositions and methods
US8178539B2 (en) 2006-09-06 2012-05-15 3M Innovative Properties Company Substituted 3,4,6,7-tetrahydro-5H-1,2a,4a,8-tetraazacyclopenta[cd]phenalenes and methods
US20080149123A1 (en) * 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles
LT2487166T (lt) 2007-02-23 2016-11-10 Gilead Sciences, Inc. Terapinių agentų farmakokinetinių savybių moduliatoriai
SI2296633T1 (sl) * 2008-05-02 2015-11-30 Gilead Sciences, Inc. Uporaba trdnih nosilnih delcev za izboljšanje predelovalnih sposobnosti farmacevtskega sredstva
US20110033515A1 (en) * 2009-08-04 2011-02-10 Rst Implanted Cell Technology Tissue contacting material
WO2011084725A1 (en) * 2009-12-21 2011-07-14 3M Innovative Properties Company 4-AMINO-2-(ETHOXYMETHYL)-1-(2-HYDROXY-2-METHYLPROPYL)-1H-IMIDAZO[4,5-c]QUINOLIN-5-IUM 1-HYDROXYNAPHTHALENE-2-CARBOXYLATE COMPOSITIONS AND METHODS
SMT201700182T1 (it) 2010-08-17 2017-05-08 3M Innovative Properties Company Composizioni di composti modificanti la risposta immunitaria lipidati, formulazioni e metodi
BR112013031028A2 (pt) 2011-06-03 2016-11-29 3M Innovative Properties Co conectores heterobifuncionais com segmentos de polietileno glicol e conjugados de modificadores de resposta imunológica feitos a partir deles
BR112013031039B1 (pt) 2011-06-03 2020-04-28 3M Innovative Properties Co compostos de hidrazino 1h-imidazoquinolina-4-aminas, conjugados feitos destes compostos, composição e composição farmacêutica compreendendo ditos compostos e conjugados, usos dos mesmos e método de fabricação do conjugado
US20130023736A1 (en) 2011-07-21 2013-01-24 Stanley Dale Harpstead Systems for drug delivery and monitoring
CA2871490C (en) 2012-04-27 2022-10-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of cpg oligonucleotides co-formulated with an antibiotic to accelerate wound healing
CA2871711A1 (en) 2012-05-04 2013-11-07 Pfizer Inc. Prostate-associated antigens and vaccine-based immunotherapy regimens
KR102237799B1 (ko) 2012-11-14 2021-04-08 더블유.알. 그레이스 앤드 캄파니-콘. 생물학적 활성 물질 및 비-정렬된 무기 산화물을 함유하는 조성물
TWI691335B (zh) 2014-07-09 2020-04-21 英屬開曼群島商博笛生物科技有限公司 用於治療腫瘤的抗pd-l1組合
US20160058718A1 (en) * 2014-09-02 2016-03-03 Michael Basara Formulation and method of treating chronic wounds and preventing bacterial infections
WO2016063265A2 (pt) * 2014-10-24 2016-04-28 Palmeira De Oliveira Rita Manuela Formulação tópica para o tratamento de infeções na pele ou mucosas, método de preparação e seus usos
IL267929B2 (en) 2017-01-10 2023-03-01 Nektar Therapeutics Multi-armed polymer conjugates of tlr agonistic compounds and related immunotherapeutic methods
US11306083B2 (en) 2017-12-20 2022-04-19 3M Innovative Properties Company Amide substituted imidazo[4,5-C]quinoline compounds with a branched chain linking group for use as an immune response modifier
SG11202109809WA (en) 2019-02-13 2021-10-28 DEBx Medical Holding BV Compositions for removing necrotic or infected tissues from body surface lesions and from oral cavity
WO2020226889A1 (en) * 2019-05-07 2020-11-12 Wellstat Therapeutics Corporation Formulations of uridine triacetate in triacetin

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA831186B (en) * 1982-03-22 1983-11-30 Upjohn Ltd Gelled pge2/triacetin solutions
IL73534A (en) * 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
CA1272953A (en) * 1984-10-08 1990-08-21 Yuji Makino Pharmaceutical composition for external use containing active-type vitamin d.sub.3
ES2032861T3 (es) 1986-07-14 1993-03-01 Sandoz Ag Procedimiento para preparar un medicamento a base de 5-hetero- o aril-substituido-imidazo (2,1-a)isoquinolina.
US4788064A (en) * 1987-07-31 1988-11-29 Warner-Lambert Company Transdermal delivery system
US4814173A (en) * 1987-09-08 1989-03-21 Warner-Lambert Company Silicone elastomer transdermal matrix system
US5238944A (en) * 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
IL92537A (en) * 1988-12-15 1994-04-12 Riker Laboratories Inc Topical preparations and dermal systems containing 1-isobutyl-H1-imidazo [C-4,5] quinoline-4-amine
DK0385630T3 (da) * 1989-02-27 1997-05-12 Riker Laboratories Inc 1H-imidazo(4,5-c)quinolin-4-aminer som antivirale midler
US5389640A (en) * 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
DK0872478T3 (da) * 1991-03-01 2003-03-31 Minnesota Mining & Mfg Mellemprodukter til fremstilling af 1-substituerede, 2-substituerede 1H-imidazo[4,5-c]quinolin-4-aminer
DE4117249C2 (de) * 1991-05-27 1998-05-14 Christian Dr Stief Linsidomin zur Behandlung erektiler Dysfunktionen

Also Published As

Publication number Publication date
NZ335821A (en) 2001-04-27
KR100503716B1 (ko) 2005-07-26
DE69723721T2 (de) 2004-04-15
CA2273094A1 (en) 1998-06-11
IL130065A0 (en) 2000-02-29
KR20000069233A (ko) 2000-11-25
CA2273094C (en) 2005-08-16
US5939090A (en) 1999-08-17
NO325684B1 (no) 2008-07-07
AU5368698A (en) 1998-06-29
ES2200206T3 (es) 2004-03-01
BR9713677B1 (pt) 2009-05-05
WO1998024436A3 (en) 1998-08-06
IL130065A (en) 2004-06-20
AU723897B2 (en) 2000-09-07
CZ195599A3 (cs) 1999-09-15
EP0942724B1 (de) 2003-07-23
HUP0000568A3 (en) 2001-01-29
CZ301713B6 (cs) 2010-06-02
NO992638D0 (no) 1999-06-01
JP4615633B2 (ja) 2011-01-19
DK0942724T3 (da) 2003-11-17
JP2001501968A (ja) 2001-02-13
BR9713677A (pt) 2000-03-28
HU229599B1 (hu) 2014-02-28
US20020015715A1 (en) 2002-02-07
ATE245422T1 (de) 2003-08-15
EP0942724A2 (de) 1999-09-22
US6365166B2 (en) 2002-04-02
WO1998024436A2 (en) 1998-06-11
NO992638L (no) 1999-07-16
PT942724E (pt) 2003-12-31
HUP0000568A2 (hu) 2000-10-28

Similar Documents

Publication Publication Date Title
DE69723721D1 (de) Gelformulierungen zur topischen arzneimittelzufuhr
DE60026538D1 (de) Pharmazeutische zubereitungen die clavulansäure oder derivate enthalten zur behandlund von neurologischen störungen
AU4261097A (en) Compositions and methods for topical application of therapeutic agents
CY2014005I2 (el) Τοπικα συστηματα παροχης γελης για την θεραπευτικη αντιμετωπιση των διαταραχων δερματος
ATE429904T1 (de) Topisch anwendbare arzneipräparate und verfahren zur behandlung
CA2319515A1 (en) Anhydrous topical skin preparations
HUP0000299A1 (hu) Késleltetett hatóanyag-leadású gyógyszerkészítmények
MXPA03010991A (es) Composicion permeable a la piel que comprende inhibidor de ciclooxigenasa-a selectivo y alcohol monohidrico.
PL344111A1 (en) Formulations for the prevention or the treatment of diseases affecting mucosae or skin, or for pregnancy prevention, and an applicator for the delivery of topical formulations into mucosal cavities
AU2002341366A1 (en) Pharmaceutical preparations useful for treating tumors and lesions of the skin and the mucuous membranes
ITMI981586A0 (it) Vitamina e e suoi esteri per l'uso nel trattamento topico di patologie delle mucose
IT8920898A0 (it) Uso di sucralfato gel umido per il trattamento di ulcere del derma e come veicolo di farmaci ad attivita' topica.
WO1999012545A3 (en) Medicaments containing acyclovir
WO2000016786A3 (en) Oxihumic acid and its use in the treatment of various conditions
MY110074A (en) Pharmacuetical formulation.
AU4040195A (en) Topical composition containing penciclovir
ATE241974T1 (de) Nimelulide enthaltendes pharmazeutisches präparat zur oralen verabreichung
DE69825322D1 (de) Topische carbamazepin-formulierungen und deren verwendung
EP1159956A3 (de) Wasserfreie topische Zubereitungen für die Haut
RU94004903A (ru) Противоопухолевые и иммуномодулирующие средства и способы лечения онкологических больных, кожных заболеваний и трофических язв
RU94022334A (ru) Способ лечения и профилактики инвазионных заболеваний
SI0898477T1 (en) Topical administration of premafloxacin for the treatment of systemic bacterial diseases
IT1257884B (it) Formulazioni farmaceutiche per il trattamento di malattie periferiche vascolari a base di vincamina o di un suo sale farmaceuticamente accettabile.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition